Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report

Article reviews a case report of depigmentation after three months of pembrolizumab for non-small-cell lung cancer. The patient’s excellent response to treatment indicates that cutaneous immune-related adverse events might be associated with increased efficacy.

British Journal of Clinical Pharmacology